Comparison of quantitative imaging parameters using cardiovascular magnetic resonance between cardiac amyloidosis and hypertrophic cardiomyopathy: inversion time scout versus T1 mapping

被引:0
作者
Bo Da Nam
Sung Mok Kim
Hye Na Jung
Yiseul Kim
Yeon Hyeon Choe
机构
[1] Sungkyunkwan University School of Medicine,Department of Radiology, Samsung Medical Center
[2] Soonchunhyang University College of Medicine,Department of Radiology, Soonchunhyang University Seoul Hospital
[3] Samsung Medical Center,Cardiovascular Imaging Center, Heart Vascular and Stroke Institute
[4] Korea University College of Medicine,Department of Radiology, Korea University Guro Hospital
[5] Sungkyunkwan University School of Medicine,Department of Radiology and Cardiovascular Imaging Center, Cardiac and Vascular Center, Samsung Medical Center
来源
The International Journal of Cardiovascular Imaging | 2018年 / 34卷
关键词
Amyloidosis; Cardiovascular magnetic resonance; Extracellular volume; Hypertrophic cardiomyopathy; Inversion time;
D O I
暂无
中图分类号
学科分类号
摘要
To compare inversion time (TI) parameters, native T1, and extracellular volume (ECV) on cardiac magnetic resonance (CMR) imaging between patients with cardiac amyloidosis (CA) or hypertrophic cardiomyopathy (HCMP). Forty six patients with biopsy-confirmed CA and 30 patients with HCMP who underwent CMR were included. T1 and TI values were measured in the septum and cavity of the left ventricle on T1 mapping and TI scout images. TI values were selected at nulling point for each myocardium and blood pool. Native T1, ECV, and TI interval values were significantly different between the CA (1170.5 ± 86.4 ms, 56.7 ± 12.2, − 11.5 ± 28.4 ms) and HCMP (1059.5 ± 63.4 ms, 28.5 ± 5.8, 66.2 ± 25.4 ms) (all p < 0.001). The diagnostic performance of the TI interval (area under the ROC curve, 0.975) was not inferior to that of the ECV (0.980, p = 0.776), and it was superior to that of the native T1 (0.845, p = 0.004). The diagnostic performance of TI interval was comparable to that of ECV for differential diagnosis between CA and HCMP. TI interval showed the feasibility as quantitative CMR parameter when T1 mapping images are not available.
引用
收藏
页码:1769 / 1777
页数:8
相关论文
共 185 条
[1]  
Kyle RA(1986)Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases Blood 68 220-224
[2]  
Greipp PR(2007)The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology J Am Coll Cardiol 50 1914-1931
[3]  
O’Fallon WM(2005)Cardiovascular magnetic resonance in cardiac amyloidosis Circulation 111 122-124
[4]  
Cooper LT(2006)MR findings in cardiac amyloidosis AJR Am J Roentgenol 186 1682-1685
[5]  
Baughman KL(2008)Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy J Am Coll Cardiol 51 1022-1030
[6]  
Feldman AM(2003)Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study Lancet 361 374-379
[7]  
Frustaci A(2010)Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis JACC Cardiovasc Imaging 3 155-164
[8]  
Jessup M(2005)Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies Eur Heart J 26 1461-1474
[9]  
Kuhl U(2003)Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance J Am Coll Cardiol 41 1561-1567
[10]  
Levine GN(2002)Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy Tex Heart Inst J 29 176-180